IND Expansion IND filing and upcoming NST-628 progress indicate a moving clinical program, creating an opportunity to engage in companion diagnostics, CRO partnerships, and early access conversations with translational bioanalytics providers and contract research organizations.

Strategic Partnerships Recent HitGen collaboration for DNA-encoded library screening suggests a pathway to scalable hit discovery services; potential to pitch broader collaboration on library services, hit validation, and integrated discovery pipelines.

Precision Oncology Focus Mission to expand precision medicine and deliver first- and best-in-class oncology treatments positions Nested as a candidate for late-stage asset co-development discussions, oncology-focused contract manufacturing, and translational science support.

Funding Momentum Significant prior funding and a recent IND enablement signal validate the company’s growth trajectory; opportunities exist to engage in strategic advisory roles, capital introductions, and funding-enabled partnerships with CROs and biotech service vendors.

Technology Enablement Tech stack involving data-driven and software-enabled processes alongside traditional bio R&D implies openness to integrated software as a service, data management, collaboration platforms, and IP-centric tooling collaborations for drug discovery efficiency.